Share Price and Basic Stock Data
Last Updated: February 12, 2026, 9:38 pm
| PEG Ratio | 2.11 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Vimta Labs Ltd, operating in the Medical Research Services industry, reported a market capitalization of ₹2,190 Cr and a share price of ₹491. The company demonstrated a robust revenue trajectory, with sales rising from ₹276 Cr in FY 2022 to ₹315 Cr in FY 2023. The trailing twelve months (TTM) sales stood at ₹384 Cr, indicating a continuous upward trend. Quarterly sales figures reflected fluctuations, with the highest in June 2025 at ₹98 Cr and the lowest in September 2023 at ₹64 Cr. This revenue growth aligns with the company’s strategic focus on expanding its service offerings, though recent quarterly declines could indicate seasonal variations or market challenges. The operating profit margin (OPM) averaged 35% over recent quarters, underscoring the company’s ability to maintain profitability amidst varying sales levels. As the medical research sector continues to evolve, Vimta Labs is well-positioned to leverage its established market presence for sustained growth.
Profitability and Efficiency Metrics
Vimta Labs reported a net profit of ₹79 Cr, with a return on equity (ROE) of 19.4% and a return on capital employed (ROCE) of 25.2%, indicating efficient utilization of equity and overall capital. The operating profit for FY 2023 was ₹94 Cr, translating to an operating profit margin (OPM) of 30%, which rose to 35% in FY 2025. The interest coverage ratio (ICR) stood at an impressive 42.79x, suggesting that the company is highly capable of meeting its interest obligations. The cash conversion cycle (CCC) was reported at 235 days, indicating a relatively longer duration for converting investments in inventory and receivables into cash. This metric, while manageable, could benefit from further optimization to enhance liquidity. Overall, Vimta Labs showcases strong profitability metrics, though attention to working capital management could further improve its financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Vimta Labs reflects strong financial stability, highlighted by total reserves of ₹407 Cr against borrowings of only ₹7 Cr. This low level of debt, with a debt-to-equity ratio of 0.06, indicates a conservative capital structure, minimizing financial risk. The current ratio stood at 2.91, well above the typical threshold of 1, suggesting ample liquidity to meet short-term obligations. Additionally, the price-to-book value (P/BV) ratio was recorded at 3.08x, indicating that the market values the company at a premium to its book value, which may reflect investor confidence in future growth prospects. However, with a cash earning retention ratio of 94.12%, the company is retaining most of its earnings for reinvestment, which could be beneficial for future expansion. The financial ratios suggest a healthy balance sheet, underscoring Vimta Labs’ ability to navigate market challenges effectively.
Shareholding Pattern and Investor Confidence
As of September 2025, the shareholding pattern of Vimta Labs revealed that promoters held 35.99% of the equity, a slight decline from previous periods, indicating a potential dilution of control. Foreign institutional investors (FIIs) increased their stake to 4.33%, while domestic institutional investors (DIIs) held a modest 0.87%. The public shareholding stood at 58.80%, reflecting a broad base of retail investors. Over the past year, the number of shareholders surged from 18,916 to 55,933, indicating growing investor interest and confidence in the company. This increase in shareholder base can be attributed to the company’s strong financial performance and growth prospects in the medical research sector. The diversification of the shareholder structure could mitigate risks associated with concentrated ownership, enhancing corporate governance and operational transparency.
Outlook, Risks, and Final Insight
Vimta Labs is poised for continued growth, driven by its established market position and strong financial fundamentals. However, the company faces risks related to fluctuating quarterly revenues and a longer cash conversion cycle, which could impact liquidity. Additionally, the increasing competition in the medical research services sector could pressure margins. On the positive side, the company’s low debt levels and robust profitability metrics provide a cushion against economic downturns. If Vimta Labs can effectively manage its working capital and leverage its strong balance sheet, it stands to capitalize on emerging opportunities in the healthcare sector. In the event of successful strategic initiatives, the company may enhance its market share and profitability, while any significant downturn in the sector could pose challenges. Overall, Vimta Labs presents a compelling investment case, contingent upon its ability to navigate the evolving landscape of medical research services while maintaining operational efficiency and financial health.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Choksi Laboratories Ltd | 84.1 Cr. | 121 | 237/95.0 | 52.9 | 35.2 | 0.00 % | 9.20 % | 6.63 % | 10.0 |
| Vimta Labs Ltd | 2,189 Cr. | 491 | 903/372 | 28.9 | 93.3 | 0.20 % | 25.2 % | 19.4 % | 2.00 |
| Industry Average | 2,189.00 Cr | 306.00 | 40.90 | 64.25 | 0.10% | 17.20% | 13.02% | 6.00 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 76 | 81 | 82 | 64 | 73 | 73 | 75 | 85 | 90 | 94 | 98 | 102 | 99 |
| Expenses | 55 | 57 | 58 | 48 | 50 | 47 | 49 | 55 | 57 | 61 | 64 | 68 | 64 |
| Operating Profit | 21 | 24 | 24 | 17 | 23 | 26 | 26 | 30 | 33 | 33 | 34 | 34 | 34 |
| OPM % | 27% | 29% | 29% | 26% | 31% | 36% | 35% | 35% | 37% | 35% | 35% | 34% | 35% |
| Other Income | 1 | 1 | 1 | 0 | -1 | -1 | -1 | -1 | 5 | 2 | 2 | 3 | 0 |
| Interest | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 10 | 9 | 10 | 10 | 11 |
| Profit before tax | 14 | 16 | 16 | 8 | 13 | 16 | 17 | 20 | 28 | 25 | 25 | 26 | 23 |
| Tax % | 27% | 23% | 25% | 25% | 25% | 24% | 26% | 24% | 23% | 27% | 25% | 24% | 25% |
| Net Profit | 10 | 12 | 12 | 6 | 9 | 12 | 12 | 15 | 22 | 18 | 19 | 20 | 18 |
| EPS in Rs | 2.25 | 2.77 | 2.63 | 1.34 | 2.14 | 2.79 | 2.77 | 3.44 | 4.84 | 4.12 | 4.24 | 4.47 | 3.94 |
Last Updated: February 3, 2026, 3:46 pm
Below is a detailed analysis of the quarterly data for Vimta Labs Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 99.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Sep 2025) to 99.00 Cr., marking a decrease of 3.00 Cr..
- For Expenses, as of Dec 2025, the value is 64.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 68.00 Cr. (Sep 2025) to 64.00 Cr., marking a decrease of 4.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 34.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 34.00 Cr..
- For OPM %, as of Dec 2025, the value is 35.00%. The value appears strong and on an upward trend. It has increased from 34.00% (Sep 2025) to 35.00%, marking an increase of 1.00%.
- For Other Income, as of Dec 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Sep 2025) to 0.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Dec 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00 Cr..
- For Depreciation, as of Dec 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Sep 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Sep 2025) to 23.00 Cr., marking a decrease of 3.00 Cr..
- For Tax %, as of Dec 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Sep 2025) to 25.00%, marking an increase of 1.00%.
- For Net Profit, as of Dec 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Sep 2025) to 18.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 3.94. The value appears to be declining and may need further review. It has decreased from 4.47 (Sep 2025) to 3.94, marking a decrease of 0.53.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:25 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 127 | 116 | 138 | 154 | 183 | 213 | 181 | 209 | 276 | 315 | 289 | 344 | 384 |
| Expenses | 101 | 99 | 119 | 127 | 138 | 155 | 151 | 156 | 196 | 222 | 195 | 222 | 250 |
| Operating Profit | 26 | 17 | 19 | 27 | 45 | 58 | 30 | 53 | 80 | 94 | 94 | 122 | 134 |
| OPM % | 20% | 15% | 14% | 18% | 25% | 27% | 17% | 25% | 29% | 30% | 33% | 35% | 35% |
| Other Income | 3 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 0 | 3 | -4 | 5 | 11 |
| Interest | 2 | 1 | 1 | 2 | 5 | 5 | 4 | 2 | 2 | 3 | 2 | 2 | 2 |
| Depreciation | 9 | 11 | 10 | 10 | 16 | 20 | 21 | 23 | 23 | 31 | 33 | 35 | 39 |
| Profit before tax | 18 | 7 | 8 | 17 | 26 | 35 | 8 | 28 | 55 | 64 | 55 | 90 | 104 |
| Tax % | 25% | 24% | 23% | 36% | 36% | 28% | 17% | 25% | 26% | 26% | 25% | 25% | |
| Net Profit | 13 | 5 | 6 | 11 | 16 | 25 | 7 | 21 | 41 | 47 | 41 | 67 | 79 |
| EPS in Rs | 3.00 | 1.14 | 1.45 | 2.40 | 3.72 | 5.73 | 1.57 | 4.81 | 9.29 | 10.68 | 9.26 | 15.13 | 17.67 |
| Dividend Payout % | 33% | 44% | 34% | 0% | 27% | 17% | 0% | 21% | 11% | 9% | 11% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.54% | 20.00% | 83.33% | 45.45% | 56.25% | -72.00% | 200.00% | 95.24% | 14.63% | -12.77% | 63.41% |
| Change in YoY Net Profit Growth (%) | 0.00% | 81.54% | 63.33% | -37.88% | 10.80% | -128.25% | 272.00% | -104.76% | -80.60% | -27.40% | 76.18% |
Vimta Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 8% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 58% |
| 3 Years: | 17% |
| TTM: | 51% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 72% |
| 3 Years: | 65% |
| 1 Year: | 146% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 17% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 1:51 pm
Balance Sheet
Last Updated: February 1, 2026, 4:08 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 9 |
| Reserves | 116 | 118 | 122 | 132 | 148 | 167 | 169 | 190 | 229 | 276 | 310 | 374 | 407 |
| Borrowings | 7 | 4 | 26 | 44 | 40 | 26 | 32 | 30 | 19 | 15 | 19 | 9 | 7 |
| Other Liabilities | 22 | 21 | 23 | 42 | 40 | 40 | 39 | 49 | 54 | 65 | 61 | 79 | 95 |
| Total Liabilities | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 394 | 467 | 518 |
| Fixed Assets | 90 | 88 | 88 | 88 | 140 | 135 | 131 | 128 | 162 | 168 | 166 | 230 | 240 |
| CWIP | 2 | 0 | 6 | 53 | 0 | 4 | 2 | 17 | 0 | 12 | 59 | 38 | 55 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 6 | 0 | 0 | 0 |
| Other Assets | 57 | 58 | 82 | 80 | 92 | 99 | 105 | 122 | 138 | 174 | 170 | 198 | 224 |
| Total Assets | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 394 | 467 | 518 |
Below is a detailed analysis of the balance sheet data for Vimta Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 5.00 Cr..
- For Reserves, as of Sep 2025, the value is 407.00 Cr.. The value appears strong and on an upward trend. It has increased from 374.00 Cr. (Mar 2025) to 407.00 Cr., marking an increase of 33.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 9.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 95.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.00 Cr. (Mar 2025) to 95.00 Cr., marking an increase of 16.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 518.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 467.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 51.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 240.00 Cr.. The value appears strong and on an upward trend. It has increased from 230.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 55.00 Cr.. The value appears strong and on an upward trend. It has increased from 38.00 Cr. (Mar 2025) to 55.00 Cr., marking an increase of 17.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 224.00 Cr.. The value appears strong and on an upward trend. It has increased from 198.00 Cr. (Mar 2025) to 224.00 Cr., marking an increase of 26.00 Cr..
- For Total Assets, as of Sep 2025, the value is 518.00 Cr.. The value appears strong and on an upward trend. It has increased from 467.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 51.00 Cr..
Notably, the Reserves (407.00 Cr.) exceed the Borrowings (7.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 19.00 | 13.00 | -7.00 | -17.00 | 5.00 | 32.00 | -2.00 | 23.00 | 61.00 | 79.00 | 75.00 | 113.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 81 | 82 | 100 | 101 | 111 | 100 | 117 | 128 | 102 | 93 | 110 | 113 |
| Inventory Days | 175 | 158 | 213 | 183 | 209 | 199 | 191 | 140 | 154 | 195 | 260 | 210 |
| Days Payable | 87 | 66 | 77 | 184 | 148 | 115 | 114 | 139 | 108 | 124 | 87 | 88 |
| Cash Conversion Cycle | 169 | 174 | 236 | 100 | 172 | 184 | 194 | 128 | 147 | 164 | 283 | 235 |
| Working Capital Days | 65 | 109 | 99 | 22 | 62 | 78 | 64 | 89 | 87 | 78 | 98 | 96 |
| ROCE % | 16% | 6% | 7% | 11% | 17% | 21% | 6% | 14% | 24% | 24% | 20% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 330,152 | 0.1 | 14.99 | 330,152 | 2025-04-22 17:25:16 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 78 | 0.04 | 0 | 78 | 2025-04-22 17:25:16 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 18.51 | 21.77 | 18.70 | 9.68 | 3.10 |
| Diluted EPS (Rs.) | 18.24 | 21.35 | 18.32 | 9.68 | 3.10 |
| Cash EPS (Rs.) | 33.92 | 35.65 | 29.24 | 20.12 | 12.56 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 144.20 | 127.33 | 105.83 | 87.92 | 78.19 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 144.20 | 127.33 | 105.83 | 87.92 | 78.19 |
| Revenue From Operations / Share (Rs.) | 143.55 | 143.78 | 125.86 | 95.29 | 81.73 |
| PBDIT / Share (Rs.) | 40.96 | 44.44 | 36.97 | 24.33 | 14.91 |
| PBIT / Share (Rs.) | 25.53 | 30.57 | 26.42 | 13.89 | 5.44 |
| PBT / Share (Rs.) | 24.57 | 29.37 | 25.19 | 12.91 | 3.74 |
| Net Profit / Share (Rs.) | 18.50 | 21.77 | 18.69 | 9.68 | 3.10 |
| NP After MI And SOA / Share (Rs.) | 18.50 | 21.77 | 18.69 | 9.68 | 3.10 |
| PBDIT Margin (%) | 28.52 | 30.91 | 29.37 | 25.52 | 18.24 |
| PBIT Margin (%) | 17.78 | 21.25 | 20.98 | 14.57 | 6.65 |
| PBT Margin (%) | 17.11 | 20.42 | 20.01 | 13.54 | 4.57 |
| Net Profit Margin (%) | 12.88 | 15.13 | 14.85 | 10.16 | 3.78 |
| NP After MI And SOA Margin (%) | 12.88 | 15.13 | 14.85 | 10.16 | 3.78 |
| Return on Networth / Equity (%) | 12.82 | 17.09 | 17.66 | 11.01 | 3.95 |
| Return on Capital Employeed (%) | 16.36 | 22.17 | 22.51 | 13.92 | 6.39 |
| Return On Assets (%) | 10.25 | 13.29 | 13.45 | 7.80 | 2.78 |
| Long Term Debt / Equity (X) | 0.02 | 0.03 | 0.05 | 0.07 | 0.03 |
| Total Debt / Equity (X) | 0.06 | 0.05 | 0.08 | 0.11 | 0.13 |
| Asset Turnover Ratio (%) | 0.83 | 0.95 | 0.95 | 0.81 | 0.00 |
| Current Ratio (X) | 2.91 | 2.86 | 2.60 | 2.05 | 1.67 |
| Quick Ratio (X) | 2.46 | 2.46 | 2.24 | 1.78 | 1.37 |
| Dividend Payout Ratio (NP) (%) | 10.79 | 9.17 | 10.69 | 0.00 | 64.60 |
| Dividend Payout Ratio (CP) (%) | 5.88 | 5.60 | 6.83 | 0.00 | 15.91 |
| Earning Retention Ratio (%) | 89.21 | 90.83 | 89.31 | 0.00 | 35.40 |
| Cash Earning Retention Ratio (%) | 94.12 | 94.40 | 93.17 | 0.00 | 84.09 |
| Interest Coverage Ratio (X) | 42.79 | 37.19 | 54.56 | 24.81 | 8.76 |
| Interest Coverage Ratio (Post Tax) (X) | 20.33 | 19.21 | 29.41 | 10.87 | 2.82 |
| Enterprise Value (Cr.) | 979.08 | 670.65 | 704.61 | 372.30 | 147.42 |
| EV / Net Operating Revenue (X) | 3.08 | 2.11 | 2.53 | 1.77 | 0.81 |
| EV / EBITDA (X) | 10.78 | 6.82 | 8.62 | 6.92 | 4.47 |
| MarketCap / Net Operating Revenue (X) | 3.10 | 2.19 | 2.50 | 1.69 | 0.72 |
| Retention Ratios (%) | 89.20 | 90.82 | 89.30 | 0.00 | 35.39 |
| Price / BV (X) | 3.08 | 2.47 | 2.98 | 1.83 | 0.75 |
| Price / Net Operating Revenue (X) | 3.10 | 2.19 | 2.50 | 1.69 | 0.72 |
| EarningsYield | 0.04 | 0.06 | 0.05 | 0.06 | 0.05 |
After reviewing the key financial ratios for Vimta Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 18.51. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.51, marking a decrease of 3.26.
- For Diluted EPS (Rs.), as of Mar 24, the value is 18.24. This value is within the healthy range. It has decreased from 21.35 (Mar 23) to 18.24, marking a decrease of 3.11.
- For Cash EPS (Rs.), as of Mar 24, the value is 33.92. This value is within the healthy range. It has decreased from 35.65 (Mar 23) to 33.92, marking a decrease of 1.73.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 143.55. It has decreased from 143.78 (Mar 23) to 143.55, marking a decrease of 0.23.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 40.96. This value is within the healthy range. It has decreased from 44.44 (Mar 23) to 40.96, marking a decrease of 3.48.
- For PBIT / Share (Rs.), as of Mar 24, the value is 25.53. This value is within the healthy range. It has decreased from 30.57 (Mar 23) to 25.53, marking a decrease of 5.04.
- For PBT / Share (Rs.), as of Mar 24, the value is 24.57. This value is within the healthy range. It has decreased from 29.37 (Mar 23) to 24.57, marking a decrease of 4.80.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
- For PBDIT Margin (%), as of Mar 24, the value is 28.52. This value is within the healthy range. It has decreased from 30.91 (Mar 23) to 28.52, marking a decrease of 2.39.
- For PBIT Margin (%), as of Mar 24, the value is 17.78. This value is within the healthy range. It has decreased from 21.25 (Mar 23) to 17.78, marking a decrease of 3.47.
- For PBT Margin (%), as of Mar 24, the value is 17.11. This value is within the healthy range. It has decreased from 20.42 (Mar 23) to 17.11, marking a decrease of 3.31.
- For Net Profit Margin (%), as of Mar 24, the value is 12.88. This value exceeds the healthy maximum of 10. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 12.88. This value is within the healthy range. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
- For Return on Networth / Equity (%), as of Mar 24, the value is 12.82. This value is below the healthy minimum of 15. It has decreased from 17.09 (Mar 23) to 12.82, marking a decrease of 4.27.
- For Return on Capital Employeed (%), as of Mar 24, the value is 16.36. This value is within the healthy range. It has decreased from 22.17 (Mar 23) to 16.36, marking a decrease of 5.81.
- For Return On Assets (%), as of Mar 24, the value is 10.25. This value is within the healthy range. It has decreased from 13.29 (Mar 23) to 10.25, marking a decrease of 3.04.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 23) to 0.06, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.83. It has decreased from 0.95 (Mar 23) to 0.83, marking a decrease of 0.12.
- For Current Ratio (X), as of Mar 24, the value is 2.91. This value is within the healthy range. It has increased from 2.86 (Mar 23) to 2.91, marking an increase of 0.05.
- For Quick Ratio (X), as of Mar 24, the value is 2.46. This value exceeds the healthy maximum of 2. There is no change compared to the previous period (Mar 23) which recorded 2.46.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 10.79. This value is below the healthy minimum of 20. It has increased from 9.17 (Mar 23) to 10.79, marking an increase of 1.62.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.88. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 23) to 5.88, marking an increase of 0.28.
- For Earning Retention Ratio (%), as of Mar 24, the value is 89.21. This value exceeds the healthy maximum of 70. It has decreased from 90.83 (Mar 23) to 89.21, marking a decrease of 1.62.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.12. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 23) to 94.12, marking a decrease of 0.28.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 42.79. This value is within the healthy range. It has increased from 37.19 (Mar 23) to 42.79, marking an increase of 5.60.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 20.33. This value is within the healthy range. It has increased from 19.21 (Mar 23) to 20.33, marking an increase of 1.12.
- For Enterprise Value (Cr.), as of Mar 24, the value is 979.08. It has increased from 670.65 (Mar 23) to 979.08, marking an increase of 308.43.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.11 (Mar 23) to 3.08, marking an increase of 0.97.
- For EV / EBITDA (X), as of Mar 24, the value is 10.78. This value is within the healthy range. It has increased from 6.82 (Mar 23) to 10.78, marking an increase of 3.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
- For Retention Ratios (%), as of Mar 24, the value is 89.20. This value exceeds the healthy maximum of 70. It has decreased from 90.82 (Mar 23) to 89.20, marking a decrease of 1.62.
- For Price / BV (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 23) to 3.08, marking an increase of 0.61.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
- For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 23) to 0.04, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vimta Labs Ltd:
- Net Profit Margin: 12.88%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.36% (Industry Average ROCE: 17.2%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.82% (Industry Average ROE: 13.02%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 20.33
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.9 (Industry average Stock P/E: 40.9)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.88%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Plot Nos. 141/2 & 142, Hyderabad Telangana 500051 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Sivalinga Prasad Vasireddi | Executive Chairman |
| Ms. Harita Vasireddi | Managing Director |
| Mr. Harriman Vungal | Executive Director - Operations |
| Mr. Satya Sreenivas Neerukonda | Executive Director |
| Dr. Yadagiri R Pendri | Independent Director |
| Ms. Prameela Rani Yalamanchili | Independent Director |
| Mr. Sanjay Dave | Independent Director |
| Mr. Purnachandra Rao Gutta | Independent Director |
FAQ
What is the intrinsic value of Vimta Labs Ltd?
Vimta Labs Ltd's intrinsic value (as of 13 February 2026) is ₹476.85 which is 2.88% lower the current market price of ₹491.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,189 Cr. market cap, FY2025-2026 high/low of ₹903/372, reserves of ₹407 Cr, and liabilities of ₹518 Cr.
What is the Market Cap of Vimta Labs Ltd?
The Market Cap of Vimta Labs Ltd is 2,189 Cr..
What is the current Stock Price of Vimta Labs Ltd as on 13 February 2026?
The current stock price of Vimta Labs Ltd as on 13 February 2026 is ₹491.
What is the High / Low of Vimta Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vimta Labs Ltd stocks is ₹903/372.
What is the Stock P/E of Vimta Labs Ltd?
The Stock P/E of Vimta Labs Ltd is 28.9.
What is the Book Value of Vimta Labs Ltd?
The Book Value of Vimta Labs Ltd is 93.3.
What is the Dividend Yield of Vimta Labs Ltd?
The Dividend Yield of Vimta Labs Ltd is 0.20 %.
What is the ROCE of Vimta Labs Ltd?
The ROCE of Vimta Labs Ltd is 25.2 %.
What is the ROE of Vimta Labs Ltd?
The ROE of Vimta Labs Ltd is 19.4 %.
What is the Face Value of Vimta Labs Ltd?
The Face Value of Vimta Labs Ltd is 2.00.